New Orleans—Statin therapy using 80 mg of simvastatin daily may be on its last legs, some physicians suggest, because the drug is associated with increased risk of myopathy. In addition, when compared with the drug's efficacy at lower doses, high-dose simvastatin is minimally or no more effective in reducing low-density lipoprotein cholesterol (LDL-C) or decreasing risk of major vascular events.
The negative appraisal of high-dose simvastatin was prompted by new results from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), presented at the Scientific Sessions of the American Heart Association held here in November.
Mitka M. Researchers Worry About Myopathy Risk for Patients Taking High-Dose Simvastatin. JAMA. 2009;301(3):261–262. doi:10.1001/jama.2008.939
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.